Immunotherapy and Radiation Therapy Integration in Oncology

The integration of immunotherapy with radiation therapy represents a paradigm shift in oncological practice, seeking to exploit the complementary mechanisms of tumour eradication. Radiation therapy induces direct DNA damage in cancer cells and modulates the tumour microenvironment to enhance antigen presentation and immune cell infiltration. Immunotherapy, particularly immune checkpoint blockade, reinvigorates exhausted T cells and counters immunosuppressive pathways within the irradiated field. Synergy arises from radiation-induced immunogenic cell death, which releases neoantigens and danger signals that prime dendritic cells and activate effector lymphocytes. Nevertheless, therapeutic success demands precise control of dose fractionation, field size and timing to avoid exacerbating immune suppression by regulatory T cells or myeloid-derived suppressor cells. Advances in targeted radionuclide therapy permit delivery of radiation to disseminated disease, while novel trial designs explore optimal sequencing of radiotherapy and systemic agents. Collectively, these approaches promise to convert non-inflamed “cold” tumours into immunologically active “hot” lesions, improving local control and eliciting systemic responses against metastatic deposits.

Research from Nature Portfolio

Recent studies have shown that sparing regional lymphatics during radiotherapy enhances systemic antitumour immunity by preserving draining lymph-node function. Selective irradiation of the primary lesion combined with concurrent immune checkpoint inhibition led to robust CD8+ T-cell priming, diminished regulatory T-cell expansion and reduced metastatic burden in head and neck cancer models. This work underlines the importance of lymphatic architecture in immune-mediated tumour control.

Consensus recommendations from clinical leaders have outlined strategies to accelerate the translation of novel drug–radiotherapy combinations. These guidelines emphasise adaptive trial designs, biomarker-driven patient stratification and harmonised regulatory frameworks to validate immunomodulatory agents alongside standard radiotherapy regimens. The framework supports expedited evaluation of synergistic combinations in a range of solid tumours.

Immunotherapy and Radiation Therapy Integration in Oncology publication trend

The graph below shows the total number of articles in immunotherapy and radiation therapy integration in oncology across all publications each year (not limited to Nature Index journals).

Technical terms

Immunotherapy: Treatment that harnesses or enhances the patient’s immune system to recognise and destroy cancer cells.

Radiation therapy: The use of high-energy ionising radiation to induce DNA damage and cell death in tumours.

Tumour microenvironment (TME): The cellular and molecular milieu surrounding cancer cells, including immune cells, stromal elements and vasculature.

Abscopal effect: A systemic antitumour response observed at distant tumour sites following localized radiation therapy.

Immune checkpoint blockade: Antibody-based inhibition of regulatory pathways (e.g. PD-1/PD-L1) to restore T-cell activity against tumours.

Radioligand therapy: Delivery of radionuclides via ligands that target tumour-associated antigens or proteins.

Hypofractionation: A radiotherapy regimen delivering higher doses per fraction over fewer treatment sessions to modulate immune responses.

References

1. Antitumor efficacy and potential mechanism of FAP-targeted radioligand therapy combined with immune checkpoint blockade. Signal Transduction and Targeted Therapy (2024).
2. Clinical development of new drug–radiotherapy combinations. Nature Reviews Clinical Oncology (2016).
3. Elective nodal irradiation mitigates local and systemic immunity generated by combination radiation and immunotherapy in head and neck tumors. Nature Communications (2022).
4. Integrin αvβ3-targeted radionuclide therapy combined with immune checkpoint blockade immunotherapy synergistically enhances anti-tumor efficacy. Theranostics (2019).